In the HF setting, the EPO administration did not prove efficacy on outcome, but the possible benefit linked to the demonstration deserves large-scale trials to examine the effect and safety of anemia treatment in HF patients [94]. The gene discussed is EPO; the disease is anemia (phenotype).